2010 HESI Annual Meeting

Presentations

Assembly of Members

Welcome to HESI Assembly of Members & Board of Trustees
Dr. Marc Bonnefoi, sanofi aventis  

Introduction:  Strengthening HESI’s impact through AOM and BOT involvement.
Dr. Michael Holsapple, ILSI HESI

Highlights of HESI Outreach

Outreach in Japan
Ms. Ayako Takei, ICaRuS Japan Limited

Outreach in Europe
Ms. Syril Pettit, ILSI HESI
Dr. Michelle Embry, ILSI HESI

Assembly of Members Business Meeting

HESI Scientific Mapping
Ms. Nancy Doerrer, ILSI HESI

Emerging Issues Session

Welcome
Dr. Bhaskar Gollapudi, The Dow Chemical Company

Reports on Existing HESI Emerging Isssues Subcommittees

Methodologies for Intermittent or Short-term Exposure to Carcinogens (MISTEC)
Dr. Rory Conolly, US EPA National Center for Computational Toxicology

Distinguishing Adverse from Adaptive, Non-functional and Pharmacological Changes in Toxicology Studies
Dr. Douglas Keller, sanofi-aventis

Identification of Pharmaceuticals for Validation of TOXCAST™
Dr. Robert Chapin, Pfizer, Inc.

State of the Science: Evaluating Epigenetic Changes
Dr. Karen Augustine, Bristol-Myers Squibb Company

New Topic Areas for Consideration By HESI Constituency

Causality and Epidemiology Studies
Dr. Stephen Cole, University of North Carolina
Dr. Carol Burns, The Dow Chemical Company

Causality and Epidemiology:  Role of HESI
Dr. Carol Burns, The Dow Chemical Company
Dr. Stephen Cole, University of North Carolina   

Association of Autoimmunity with Adjuvants in Vaccines
Dr. Sarah Gould, sanori-pasteur
Dr. Jan Willem van der Laan, RIVM

Role of HESI in Adjuvants and Autoimmunity
Dr. Sarah Gould, sanofi-pasteur
Dr. Jan Willem van der Laan, RIVM 

Next Steps
Dr. Bhaskar Gollapudi, The Dow Chemical Company

State-Of-The-Science Within HESI Session

Risk Assessment in the 21st Century (RISK21) Project

Scientific Session: HESI New Strategies and Approaches for Assessing Genetic Toxicity and Its Role in Human Risk Assessment

Introduction
Dr. James Kim, HESI

Current Strategies in Assessing Genotoxic Risk
Dr. Kerry L. Dearfield, U.S. Department of Agriculture

Need for a new Approach to Genetic Toxicity Assessment:  Lessons Learned and New Opportunities
Dr. James T. MacGregor, Toxicology Consulting Services

Approaches to Follow-up Positive Results in Genetic Toxicology Tests in the Context of Human Risk Assessment
Dr. Veronique Thybaud, sanofi-aventis

New Technologies to Predict Genotoxic Risk in Humans
Dr. David Jacobson-Kram, U.S. Food and Drug Administration

Beyond Positive or Negative:  A Quantitative Approach for Interpreting Genotoxicity Data
Dr. B. Bhaskar Gollapudi, The Dow Chemical Company

Optimal Design for in vivo Mutation Studies to Inform Cancer Mode-of-Action Assessment
Dr. Martha M. Moore, U.S. Food and Drug Administration/NCTR